1037The risk factors for resistant Esherichia coli infections after prostate biopsy under fluoroquinolone prophylaxis

1037The risk factors for resistant Esherichia coli infections after prostate biopsy under fluoroquinolone prophylaxis

Background. To evaluate the risk factors of fluoroquinolone resistant or ESBL-producing E coli infections after prostate biopsy under flouroquinolone prophylaxis Methods. From January 2003 to December 2012, we evaluated the records of 2215 patients who underwent TRUS guided 12-core prostate biopsy under flouroquinolone prophylaxis. The risk factors including age, diabetes mellitus, hypertension...

Bacterial sepsis with fluoroquinolone resistant E. coli after prostate biopsy — Is fluoroquinolone prophylaxis still effective?

Molecular typing of fluoroquinolone resistant Escherichia coli isolates from patients undergoing prostate biopsy

Background: Escherichia coli (E. coli) is one of the most important infectious agents in patients undergoing prostate biopsy. It belongs to a large family of gram-negative rods, Enterobacteriaceae. This family includes members of the normal flora of the intestine that are only occasionally pathogenic. Recent considerations of rectal colonization with fluoroquinolone-resistant E. coli shows the ...

Fluoroquinolone-resistant Escherichia coli in intestinal flora of patients undergoing transrectal ultrasound-guided prostate biopsy – possible shift in biopsy prophylaxis

INTRODUCTION Infection of prostate gland following biopsy is common complication. Most common pathogen is E.coli. Since fluorochinolones are commonly prescribed as prophylaxis, infection caused by E.coli leads to complicated infections, especially due to fluoroquinolone-resistant species. The aim of this study was to evaluate the incidence of fluoroquinolone-resistant E.coli species in rectal s...

Editorial commentary: fluoroquinolone-resistant intestinal organisms and infections after prostate biopsy: shifting sands of the prevention narrative.

Transrectal ultrasound–guided prostate biopsies continue to be the gold-standard procedure for the diagnosis of prostate cancer. Prostate biopsies are being performed in growing numbers. This is due to rising longevity, an increase in screening programs, and larger numbers of men in active surveillance protocols and men requiring rebiopsy. An increasing incidence of severe infective illness aft...